Skip to main content

2026 HFM CME Symposium - Overcoming Challenges in Transthyretin Cardiac Amyloidosis

By: PRLog
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.
This CME Symposium takes place on Saturday, July 18, 2026, from 12:30 - 1:30 PM ET during the 2026 Heart Failure Management Conference in Fernandina Beach, Florida.

HAZLET, N.J. - June 30, 2026 - PRLog -- Historically, ATTR-CM was considered a rare disease; however, it is now recognized as a more common cause of heart failure (HF) than previously thought. Despite recent attention to ATTR-CM, the condition is significantly underdiagnosed. Timely diagnosis is crucial, as it has the potential to reduce mortality and HF hospitalization when treated with targeted therapies. In this symposium, ATTRCM experts (symposium chair Dr. Mathew Maurer, faculty members Dr. Jan Griffin and Dr. Frederick Ruberg), will provide attendees with best practices for evaluating, diagnosing, and treating patients with ATTR-CM.

Click here for more information

CHAIR

Mathew Maurer, MD

Arnold and Arlene Goldstein Professor of Cardiology
Professor of Medicine
Columbia University Irving Medical Center
Vagelos College of Physicians & Surgeons
New York, New York

FACULTY

Jan Griffin, MD

Associate Professor of Medicine
Medical University of South Carolina
Charleston, South Carolina

Frederick Ruberg, MD
Thomas J. Ryan Professor of Cardiovascular Medicine
Chief, Cardiovascular Medicine
Professor of Radiology
Boston University Chobanian & Avedisian School of Medicine
Boston Medical Center
Boston, Massachusetts

Educational Objectives

- Recognize the cardiac and extracardiac red flags which raise suspicion for ATTR-CM.
- Describe the diagnostic testing components to quickly and accurately diagnose ATTR-CM.
- Summarize current recommendations for use of HF GDMT in ATTR-CM patients and the evolving evidence for Silencers and Stabilizers for ATTR-CM.
- Identify the recommended parameters for monitoring disease progression in ATTR-CM.

Target Audience
This program is intended for clinicians who manage patients with heart failure.

Educational Grant
Voxmedia gratefully acknowledges the independent educational grant provided by Alnylam Pharmaceuticals, Inc. and BridgeBio.

Accreditation and Credit Designation Statements
Voxmedia, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Voxmedia, LLC designates this live activity for a maximum of 1.0 AMA PRA Category Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.

The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Contact
Voxmedia, LLC
***@voxmedia.us

Photos: (Click photo to enlarge)

Voxmedia Logo HFM CME Symposium


Source: CMEPlanet

Read Full Story - 2026 HFM CME Symposium - Overcoming Challenges in Transthyretin Cardiac Amyloidosis | More news from this source

Press release distribution by PRLog
Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  241.70
+0.00 (0.00%)
AAPL  294.38
+0.00 (0.00%)
AMD  540.88
+0.00 (0.00%)
BAC  58.36
+0.00 (0.00%)
GOOG  357.89
+0.00 (0.00%)
META  612.91
+0.00 (0.00%)
MSFT  384.28
+0.00 (0.00%)
NVDA  197.58
+0.00 (0.00%)
ORCL  142.50
+0.00 (0.00%)
TSLA  425.30
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.